What is the impact of Mounjaro on mental health and mood?

Evidence on Mounjaro (tirzepatide) and mental health is mixed. Pharmacovigilance databases in Europe and the WHO have recorded a small number of psychiatric adverse events with GLP-1–based medicines (including tirzepatide)—most commonly low mood/depression and anxiety, with rare reports of suicidal thoughts. These events remain uncommon overall, and controlled data proving a direct causal link are limited. UK guidance (NICE and NHS materials) focuses on typical physical side effects and reinforces the importance of monitoring and reporting suspected adverse reactions via the MHRA Yellow Card scheme. In practice, anyone starting tirzepatide should monitor mood—especially during dose changes—and seek clinical advice promptly if experiencing new or worsening depression, anxiety, or suicidal thoughts.

• Uncommon psychiatric events have been reported with GLP-1 medicines (including tirzepatide), such as depression, anxiety, and rarely suicidal ideation.
• Pharmacovigilance studies show signals that warrant further investigation, but do not prove causation.
• UK guidance emphasises monitoring and reporting side effects and reviewing treatment where needed.
• Act urgently on suicidal thoughts, severe mood changes, or concerning symptoms; contact a clinician and report via Yellow Card.
• Discuss mental health history and current medicines with your prescriber; extra vigilance is sensible during dose increases.

Sources

• Pharmacovigilance analysis of psychiatric adverse events with GLP-1 receptor agonists (PMC)
• JAMA Network Open – GLP-1 RAs and risk of psychiatric adverse events
• European Psychiatry – Psychiatric adverse reactions signal evaluation for GLP-1 agents
• Mid & South Essex ICS – Access to tirzepatide for weight management
• NICE TA1026 – Practical guide: prescribing, reviewing and stopping tirzepatide